Epileptic encephalopathy, early infantile Cell Models for Research

Early infantile epileptic encephalopathy (EIEE), also known as Ohtahara syndrome, is a severe form of epilepsy with onset in the first three months of life. The incidence is estimated at 1 in 100,000 live births, though it may be underdiagnosed. The condition is characterized by frequent, refractory seizures, severe developmental delay, and a high mortality rate, with many affected children not surviving beyond infancy. The global burden is significant, with lifelong care needs for survivors. According to the World Health Organization (WHO), epilepsy affects over 50 million people worldwide, and EIEE represents a particularly devastating subset. The clinical impact is profound, with most patients experiencing profound intellectual disability and motor impairment. Early diagnosis is critical for management, but the heterogeneity of genetic causes complicates treatment.

EIEE is an ideal model for studying neurodevelopmental disorders due to its clear genetic basis and early onset. Over 100 genes have been implicated, including SCN1A, KCNQ2, CDKL5, and GABRG2, providing a rich landscape for mechanistic studies. The disease offers a unique opportunity to investigate neuronal excitability, synaptic transmission, and network development. Public datasets, such as those from the NCBI Gene and ClinVar, provide extensive variant information, enabling genotype-phenotype correlations. Open questions include the precise pathophysiological mechanisms linking genetic mutations to seizure generation and the development of targeted therapies. Gene-edited cell models are essential for functional validation of these variants and for drug screening.

The pathogenesis of EIEE involves disruption of neuronal excitability and synaptic function. Key pathways include:

1. Ion Channel Dysfunction: Mutations in voltage-gated sodium (SCN1A, SCN2A) and potassium (KCNQ2, KCNQ3) channels alter action potential generation and propagation.

2. Synaptic Transmission Defects: Mutations in genes encoding synaptic proteins (e.g., STXBP1, SYNGAP1) impair neurotransmitter release and receptor trafficking.

3. Transcriptional Regulation: Mutations in transcription factors (e.g., ARX, FOXG1) disrupt neuronal differentiation and migration.

4. Metabolic Pathways: Mitochondrial dysfunction and defects in energy metabolism contribute to neuronal damage.

Data sources: TCGA (for cancer, not applicable here), COSMIC (for cancer, not applicable), ClinVar, and NCBI Gene.

Several signaling networks are disrupted in EIEE:

• • MAPK/ERK Pathway: Involved in neuronal differentiation and synaptic plasticity; mutations in upstream regulators (e.g., BRAF) can lead to abnormal activation.
• • PI3K/AKT/mTOR Pathway: Regulates cell growth and survival; hyperactivation due to mutations in PTEN or TSC1/2 leads to abnormal neuronal morphology.
• • Wnt/β-Catenin Pathway: Critical for neurodevelopment; dysregulation affects neuronal migration and polarity.
• • GABAergic Signaling: Impaired inhibitory neurotransmission due to mutations in GABA receptor subunits (e.g., GABRG2) or synthesis enzymes (e.g., GAD1).

Organoids offer a more physiologically relevant 3D environment, allowing study of neuronal network activity and cell-cell interactions. They are particularly useful for modeling early developmental defects.

• • Genetically Engineered Mouse Models (GEMMs): Mice with targeted mutations in genes like Scn1a or Kcnq2 recapitulate seizure phenotypes and are used for mechanistic studies and drug testing.
• • Patient-Derived Xenograft (PDX) Models: Not commonly used for epilepsy, but for brain tumors; for EIEE, patient-derived iPSC-derived neurons can be transplanted into mouse brains to study integration.
• • Induced Models: Chemical or electrical kindling models induce seizures in rodents, useful for studying seizure mechanisms and testing antiepileptic drugs.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise mutations in EIEE-associated genes. These models are invaluable for studying the functional consequences of specific variants in a controlled genetic background. For example:

• • SCN1A Knockout Cell Lines: Generated in SH-SY5Y or iPSC-derived neurons to study loss-of-function effects on sodium currents.
• • KCNQ2 Knock-In Lines: Introducing a patient-specific missense mutation (e.g., p.Arg207Trp) to assess dominant-negative effects.
• • CDKL5 Knockout Lines: To investigate kinase activity and downstream signaling.

These gene-edited models are commercially available from reputable sources, with sequence verification and quality control, accelerating research without the need for in-house editing.

Gene-edited cell lines are used to validate the pathogenicity of variants identified in patients. For example, introducing a SCN1A mutation into a neuronal cell line and measuring sodium currents can confirm the functional impact. Knockout lines help identify genes essential for neuronal function, while knock-in lines allow study of specific mutations. These models are also used in CRISPR screens to identify genetic modifiers that suppress or enhance the disease phenotype.

Isogenic pairs (wild-type vs. mutant) are ideal for high-throughput drug screening. For instance, a KCNQ2 mutant cell line can be used to screen for compounds that enhance potassium channel activity. Resistance to antiepileptic drugs can be modeled by chronic exposure of mutant lines to drugs, allowing identification of resistance mechanisms and development of next-generation therapies.

CRISPR-based synthetic lethality screens can identify genes that, when silenced, selectively kill mutant cells but not wild-type cells. This approach can uncover novel therapeutic targets and biomarkers for patient stratification. For example, in a SCN1A knockout background, screening for genes whose knockdown causes cell death may reveal vulnerabilities that can be exploited therapeutically.